Annual EBITDA
-$39.43 M
+$8.98 M+18.55%
01 June 2022
Summary:
Pluristem Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$39.43 million, with the most recent change of +$8.98 million (+18.55%) on 01 June 2022. During the last 3 years, it has risen by +$8.98 million (+18.55%).PSTI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$5.97 M
+$2.76 M+31.60%
01 September 2022
Summary:
Pluristem Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$5.97 million, with the most recent change of +$2.76 million (+31.60%) on 01 September 2022.PSTI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$34.57 M
+$4.89 M+12.40%
01 September 2022
Summary:
Pluristem Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$34.57 million, with the most recent change of +$4.89 million (+12.40%) on 01 September 2022.PSTI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +18.6% | +45.0% | +32.3% |
| 5 y5 years | -18.3% | +11.2% | -9.4% |
PSTI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | >+9999.0% | >+9999.0% | >+9999.0% |
Pluristem Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$5.97 M(-31.6%) | -$34.57 M(-12.4%) |
| June 2022 | -$39.43 M(-18.6%) | -$8.73 M(-8.5%) | -$39.46 M(-12.4%) |
| Mar 2022 | - | -$9.55 M(-7.4%) | -$45.05 M(-8.6%) |
| Dec 2021 | - | -$10.31 M(-5.1%) | -$49.27 M(-3.5%) |
| Sept 2021 | - | -$10.87 M(-24.2%) | -$51.03 M(+5.8%) |
| June 2021 | -$48.42 M(+73.5%) | -$14.33 M(+4.1%) | -$48.26 M(+14.7%) |
| Mar 2021 | - | -$13.76 M(+13.9%) | -$42.09 M(+19.0%) |
| Dec 2020 | - | -$12.08 M(+49.3%) | -$35.37 M(+20.8%) |
| Sept 2020 | - | -$8.09 M(-0.9%) | -$29.27 M(+4.9%) |
| June 2020 | -$27.91 M(-16.3%) | -$8.16 M(+16.0%) | -$27.91 M(+3.5%) |
| Mar 2020 | - | -$7.04 M(+17.6%) | -$26.97 M(-9.4%) |
| Dec 2019 | - | -$5.98 M(-11.1%) | -$29.75 M(-5.9%) |
| Sept 2019 | - | -$6.73 M(-6.9%) | -$31.61 M(-5.2%) |
| June 2019 | -$33.34 M(+38.3%) | -$7.22 M(-26.4%) | -$33.34 M(+24.5%) |
| Mar 2019 | - | -$9.82 M(+25.4%) | -$26.79 M(+4.9%) |
| Dec 2018 | - | -$7.83 M(-7.5%) | -$25.52 M(-0.5%) |
| Sept 2018 | - | -$8.47 M(+1173.2%) | -$25.65 M(+6.4%) |
| June 2018 | -$24.11 M(-6.7%) | -$665.00 K(-92.2%) | -$24.11 M(-18.3%) |
| Mar 2018 | - | -$8.56 M(+7.5%) | -$29.50 M(+3.0%) |
| Dec 2017 | - | -$7.96 M(+14.9%) | -$28.63 M(+7.0%) |
| Sept 2017 | - | -$6.92 M(+14.4%) | -$26.76 M(+3.6%) |
| June 2017 | -$25.84 M(+22.1%) | -$6.05 M(-21.2%) | -$25.84 M(+1.7%) |
| Mar 2017 | - | -$7.69 M(+26.1%) | -$25.40 M(+3.5%) |
| Dec 2016 | - | -$6.10 M(+1.5%) | -$24.55 M(+10.8%) |
| Sept 2016 | - | -$6.00 M(+7.0%) | -$22.15 M(+4.6%) |
| June 2016 | -$21.17 M(-8.7%) | -$5.61 M(-17.9%) | -$21.17 M(+1.8%) |
| Mar 2016 | - | -$6.84 M(+85.1%) | -$20.79 M(-0.9%) |
| Dec 2015 | - | -$3.69 M(-26.5%) | -$20.99 M(-9.1%) |
| Sept 2015 | - | -$5.03 M(-4.0%) | -$23.09 M(-0.4%) |
| June 2015 | -$23.19 M(-10.6%) | -$5.24 M(-25.5%) | -$23.19 M(-4.1%) |
| Mar 2015 | - | -$7.03 M(+21.3%) | -$24.18 M(-6.8%) |
| Dec 2014 | - | -$5.80 M(+13.1%) | -$25.96 M(-2.7%) |
| Sept 2014 | - | -$5.13 M(-17.7%) | -$26.67 M(+2.8%) |
| June 2014 | -$25.95 M(+22.5%) | -$6.23 M(-29.3%) | -$25.95 M(-2.1%) |
| Mar 2014 | - | -$8.81 M(+35.2%) | -$26.50 M(+13.7%) |
| Dec 2013 | - | -$6.51 M(+48.1%) | -$23.30 M(+8.2%) |
| Sept 2013 | - | -$4.40 M(-35.1%) | -$21.53 M(+1.6%) |
| June 2013 | -$21.19 M(+45.2%) | -$6.78 M(+20.6%) | -$21.19 M(+16.0%) |
| Mar 2013 | - | -$5.62 M(+18.6%) | -$18.26 M(+6.5%) |
| Dec 2012 | - | -$4.74 M(+16.7%) | -$17.14 M(+18.9%) |
| Sept 2012 | - | -$4.06 M(+5.5%) | -$14.42 M(-1.2%) |
| June 2012 | -$14.60 M | -$3.85 M(-14.4%) | -$14.60 M(+2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$4.50 M(+123.1%) | -$14.22 M(+15.2%) |
| Dec 2011 | - | -$2.02 M(-52.4%) | -$12.34 M(-5.6%) |
| Sept 2011 | - | -$4.24 M(+22.0%) | -$13.07 M(+24.2%) |
| June 2011 | -$10.52 M(+45.5%) | -$3.47 M(+32.5%) | -$10.52 M(+20.7%) |
| Mar 2011 | - | -$2.62 M(-4.8%) | -$8.72 M(+5.0%) |
| Dec 2010 | - | -$2.75 M(+63.3%) | -$8.30 M(+13.4%) |
| Sept 2010 | - | -$1.68 M(+1.3%) | -$7.33 M(-9.5%) |
| June 2010 | -$7.23 M(+13.2%) | -$1.66 M(-24.6%) | -$8.10 M(+0.9%) |
| Mar 2010 | - | -$2.21 M(+24.5%) | -$8.03 M(+4.4%) |
| Dec 2009 | - | -$1.77 M(-27.9%) | -$7.69 M(+15.0%) |
| Sept 2009 | - | -$2.46 M(+54.1%) | -$6.69 M(+4.7%) |
| June 2009 | -$6.38 M(-38.0%) | -$1.59 M(-14.6%) | -$6.38 M(-14.6%) |
| Mar 2009 | - | -$1.87 M(+142.0%) | -$7.47 M(-10.2%) |
| Dec 2008 | - | -$771.00 K(-64.2%) | -$8.32 M(-17.6%) |
| Sept 2008 | - | -$2.15 M(-19.7%) | -$10.09 M(-2.0%) |
| June 2008 | -$10.30 M(+70.2%) | -$2.68 M(-1.0%) | -$10.30 M(-2.0%) |
| Mar 2008 | - | -$2.71 M(+6.6%) | -$10.52 M(+9.7%) |
| Dec 2007 | - | -$2.54 M(+7.7%) | -$9.58 M(+25.8%) |
| Sept 2007 | - | -$2.36 M(-18.5%) | -$7.62 M(+29.0%) |
| June 2007 | -$6.05 M(+192.7%) | -$2.90 M(+62.9%) | -$5.91 M(+60.6%) |
| Mar 2007 | - | -$1.78 M(+207.4%) | -$3.68 M(+49.9%) |
| Dec 2006 | - | -$579.00 K(-10.6%) | -$2.45 M(+6.7%) |
| Sept 2006 | - | -$648.00 K(-3.3%) | -$2.30 M(+11.2%) |
| June 2006 | -$2.07 M(-15.9%) | -$669.80 K(+20.6%) | -$2.07 M(+12.6%) |
| Mar 2006 | - | -$555.30 K(+30.6%) | -$1.84 M(-26.4%) |
| Dec 2005 | - | -$425.20 K(+1.9%) | -$2.50 M(+2.2%) |
| Sept 2005 | - | -$417.10 K(-5.0%) | -$2.44 M(-0.6%) |
| June 2005 | -$2.46 M(-69.8%) | -$439.20 K(-63.8%) | -$2.46 M(-70.7%) |
| Mar 2005 | - | -$1.21 M(+226.1%) | -$8.40 M(+1.2%) |
| Dec 2004 | - | -$372.40 K(-13.8%) | -$8.30 M(+0.5%) |
| Sept 2004 | - | -$432.20 K(-93.2%) | -$8.27 M(+1.7%) |
| June 2004 | -$8.13 M(+4189.8%) | -$6.38 M(+473.5%) | -$8.13 M(+325.6%) |
| Mar 2004 | - | -$1.11 M(+232.2%) | -$1.91 M(+137.7%) |
| Dec 2003 | - | -$335.20 K(+13.4%) | -$803.50 K(+64.6%) |
| Sept 2003 | - | -$295.60 K(+78.3%) | -$488.30 K(+131.9%) |
| June 2003 | -$189.50 K(+154.4%) | -$165.80 K(+2302.9%) | -$210.60 K(+212.9%) |
| Mar 2003 | - | -$6900.00(-65.5%) | -$67.30 K(-15.5%) |
| Dec 2002 | - | -$20.00 K(+11.7%) | -$79.60 K(+8.9%) |
| Sept 2002 | - | -$17.90 K(-20.4%) | -$73.10 K(+32.4%) |
| June 2002 | -$74.50 K | -$22.50 K(+17.2%) | -$55.20 K(+68.8%) |
| Mar 2002 | - | -$19.20 K(+42.2%) | -$32.70 K(+142.2%) |
| Dec 2001 | - | -$13.50 K | -$13.50 K |
FAQ
- What is Pluristem Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Pluristem Therapeutics?
- What is Pluristem Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Pluristem Therapeutics?
- What is Pluristem Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Pluristem Therapeutics?
What is Pluristem Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PSTI is -$39.43 M
What is the all time high annual EBITDA for Pluristem Therapeutics?
Pluristem Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$74.50 K
What is Pluristem Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PSTI is -$5.97 M
What is the all time high quarterly EBITDA for Pluristem Therapeutics?
Pluristem Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$6900.00
What is Pluristem Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PSTI is -$34.57 M
What is the all time high TTM EBITDA for Pluristem Therapeutics?
Pluristem Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$13.50 K